key: cord-0322355-etc04v8x authors: Young, R. J.; Demetrio de Souza Franca, P.; Pirovano, G.; Piotrowski, A. F.; Nicklin, P. J.; Riedl, C. C.; Schwartz, J.; Bale, T. A.; Donabedian, P. L.; Kossatz, S.; Burnaz, E. M.; Roberts, S.; Lyashchenko, S. K.; Miller, A. M.; Moss, N. S.; Fiasconaro, M.; Zhang, Z.; Mauguen, A.; Reiner, T.; Dunphy, M. P. title: Preclinical and first-in-human-brain-cancer applications of poly-(ADP-ribose) polymerase inhibitor PET/MR. date: 2020-07-17 journal: nan DOI: 10.1101/2020.07.13.20141036 sha: 7a0c3d5629bffd09b8c208788c572de43da5bfa1 doc_id: 322355 cord_uid: etc04v8x We report pre-clinical and first-in-human-brain-cancer data using a targeted poly(ADP-ribose)polymerase1 (PARP1) binding PET tracer, [18F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment related changes. In a pre-clinical mouse model, we illustrated that [18F]PARPi crosses the blood-brain barrier and specifically binds to PARP1 overexpressed in cancer cell nuclei. In humans, we demonstrated high [18F]PARPi uptake on PET/MR in active brain cancers and low uptake in treatment related changes, independent of blood brain-barrier disruption. Immunohistochemistry results confirmed higher PARP1 expression in cancers than non-cancers. Specificity was also corroborated by blocking fluorescent tracer uptake with excess of unlabeled PARP inhibitor in fresh cancer tissue derived from a patient. Although larger studies are necessary to confirm and further explore this tracer, we describe an encouraging role for the use of [18F]PARPi as a diagnostic tool in evaluating patients with brain cancers and possible treatment related changes. One Sentence summary: PET imaging with [ 18 F]PARPi can differentiate active brain cancer from treatment related changes with encouraging results for use during treatment follow-up. We report pre-clinical and first-in-human-brain-cancer data using a targeted poly(ADPribose)polymerase1 (PARP1) binding PET tracer, [ 18 F]PARPi, as a diagnostic tool to differentiate between brain cancers and treatment related changes. In a pre-clinical mouse model, we illustrated that [ 18 F]PARPi crosses the blood-brain barrier and specifically binds to PARP1 overexpressed in cancer cell nuclei. In humans, we demonstrated high [ 18 F]PARPi uptake on PET/MR in active brain cancers and low uptake in treatment related changes, independent of blood brain-barrier disruption. Immunohistochemistry results confirmed higher PARP1 expression in cancers than non-cancers. Specificity was also corroborated by blocking fluorescent tracer uptake with excess of unlabeled PARP inhibitor in fresh cancer tissue derived from a patient. Although larger studies are necessary to confirm and further explore this tracer, we describe an encouraging role for the use of [ 18 F]PARPi as a diagnostic tool in evaluating patients with brain cancers and possible treatment related changes. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 Positron emission tomography (PET) scans of the brain are often performed to identify and distinguish cancers from infection and from other non-cancer entities at diagnosis, most importantly from alterations related to prior treatment. Currently, [ 18 F]fluorodeoxyglucose (FDG) is the only radiotracer approved in the United States by the Food and Drug Administration (FDA); however, its sensitivity and specificity are known to be limited due to the high glucose uptake of the normal brain and also prominent uptake with postoperative and treatment related inflammatory changes (1, 2) . Because of the high physiologic uptake in normal gray matter, FDG-avid brain cancers are also often indistinct on PET brain scans. In Europe, amino acid PET radiotracers, in particular [ 18 F]fluoroethyltyrosine ([ 18 F]FET), are widely available and preferred for brain cancer imaging as normal brain tissues demonstrate less uptake of the amino acid tracer when compared to the glucose tracer, improving the cancer-tobackground contrast (3) . A recent meta-analysis indicates that [ 18 F]FET PET is probably superior to [ 18 F]FDG PET in differentiating between brain cancer progression versus treatment related changes, although the 95% confidence intervals (CI) overlapped: [ 18 F]FET PET had pooled sensitivity of 90% (95% CI, 81-95%) and specificity of 85% (95% CI, 71-93%) versus [ 18 PET with pooled sensitivity of 84% (95% CI, 72-92%) and specificity of 84% (95% CI, 69-93%) (4) . Nevertheless, the limited clinical accuracy of current brain PET tracers clearly indicates the need for new diagnostic agents. We investigate the use of fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor ([ 18 F]PARPi) as a potentially useful technique to image brain cancers. In a preclinical study with All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 5 the head-to-head comparison of [ 18 F]FET and [ 18 F] PARPi in a mouse U251 xenograft model, [ 18 F]PARPi demonstrated superior cancer visualization and superior lesion-to-contralateral uptake ratios (5) . Unlike FDG, cancer detection with [ 18 F]PARPi is not based on metabolic activity but rather on the presence of the DNA-repair enzyme poly (ADP-ribose) polymerase1 (PARP1) inside the cancer cell nuclei (6, 7) . The poly (ADP-ribose) polymerase (PARP) family of DNA repair enzymes is overexpressed in many solid cancers including brain metastases and high grade gliomas (8) (9) (10) . This overexpression is thought to represent a cellular response to the genomic instability and the frequent cell division occurring in cancer cells (11) . The difference in PARP1 expression found in between cancer and normal tissue generates the contrast that can be seen on a PET scan after injection of [ 18 F]PARPi. The [ 18 F]PARPi radiotracer is structurally similar to the PARP inhibitor olaparib (AstraZeneca, Cambridge, UK), and its ability to target the PARP1 enzyme within the cell nucleus is maintained since the structural modification of the drug is made on the cyclopropane end of the olaparib scaffold, a change that doesn't perturb target binding (12) . In pre-clinical work, [ 18 F]PARPi has been shown to visualize glioblastoma xenograft and orthotopic glioblastoma with 45x greater uptake than in the healthy brain of mouse models (13) . It has also shown 2x greater uptake in intracranial U251 xenograft cancers as compared to experimentally induced radiation necrosis (5) . This pilot study was performed to examine the feasibility of [18F]PARPi imaging in patients with brain cancers and treatment related changes. We hypothesized that active brain cancers will have high [ 18 F]PARPi uptake due to overexpression of PARP1/2 in the cancer cells. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 6 Patient distribution A total of five patients with seven enhancing lesions ≥1.5 cm were prospectively enrolled onto the study over a four-month period (December 2019 -March 2020), as summarized in Figure 2 . The median age of the patients was 49 years old (range, 34-56) and 80% were male. Patient data are summarized in Table 1 (briefly, three patients had isocitrate dehydrogenase (IDH)-wildtype primary glioblastomas and two patients had brain metastasesone with melanoma and three lesions, and one with renal cell carcinoma). Four of the seven lesions (57%) were completely resected after median 2.5 days (range, 1-31) after [ 18 F]PARPi positron emission tomography -magnetic resonance (PET/MR). Three lesions were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, . . https://doi.org/10.1101 Table 2 . Despite small cohort sizes, the median measurements of standardized uptake value (SUV) at 60 minutes (SUV60mean) and the ratio of lesion-to-normal (ratio SUV60mean) were higher in the cancer group (1.16 and 1.98, respectively) than in the treatment change group (0.45 and 0.72, respectively, p = 0.03). There was high correlation between the measurements at 60 minutes and 120 minutes, with the latter also increased in cancers with p = 0.03. In all lesions, the Ktrans and plasma volume All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 8 (VP) perfusion measurements were also higher in cancers than in treatment related changes (p = 0.03). The contrast clearance analysis trended toward higher values in cancers with p = 0.08. The volume of the enhancing lesion was not different between groups with p = 0.70. Results for individual lesions are reported in Supplementary Table 1 . Tissue specimens were also stained with the fluorescent version of the PARP inhibitor (PARPi-FL) to confirm uptake. Specific nuclear PARPi-FL uptake was seen in all cancers (lesions #2, #6 and #7). Faint PARPi-FL uptake was seen in treatment related changes (lesion #5) (Fig. 3A) , which was verified to be due to PARP1 expression by submitting the tissues to IHC. Lesion #5, with no viable cancer, had a median PARP1 expression over total tissue area of 3% (range, 1 -5%), which was significantly lower than the expression in all cancer specimens, lesions #2, #6 and #7. The median PARP1 expression over total tissue areas of those lesions were 7% (range 3 -14%), 10% (range 7 -10%) and 14% (range 11 -16%), respectively, p < 0.001, Kruskal-Wallis test ( Fig. 3B (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 Although the analysis encompasses a small number of data points (only 4 tissue specimens were available), a strong correlation was observed in between PARP1 expression and the SUVmax at 60 minutes on the PET scan (Fig. 3C) . Notably, with few observations for this analysis, lesion #7 was the influential point driving the value. (lesion #6) was scanned with [ 18 F]PARPi at 5 months after treatment with laser interstitial thermal therapy (LITT). The surgical specimen from this lesion consisted of 25% cancer and 75% reactive treatment related changes with gliosis and histiocytes (Fig. 4A) . The specimen showed greater PARP1 expression in the area of active cancer when compared to the area of treatment related changes, with an average PARP1 expression over total tissue area of 9.33 ± 1.9% versus 0.14 ± 0.06%, respectively. (Fig. 4B ). This patient also presented with areas of high and low [ 18 F]PARPi uptake on the PET/MR similar to the observed differences in PARP1 expression (Fig. 4C ). To demonstrate that [ 18 F]PARPi was specific to cancer and not just crossing a permeable blood-brain barrier, we stained (blinded from the final histopathological result) biospecimens received from surgery with the fluorescent version of the compound (PARPi-FL) and imaged under a fluorescence confocal microscope ( Fig. 3 ). PARPi-FL uptake was blocked when tissues were co-incubated with 100-fold of olaparib together with PARPi-FL (Fig. 5A ). Quantification of nuclear accumulation was carried out by the presence of PARPi-FL fluorescence signal inside the nucleus of cells. In the unblocked tissue (2,345 nuclei analyzed), 85% of cells showed PARPi-FL uptake whereas in the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org /10.1101 /10. /2020 blocked tissue (1,359 nuclei analyzed), this value was reduced to only 15%. This difference was statistically significant (p < 0.001), confirming blockade of PARPi-FL specific uptake by saturating the PARP1 enzyme with excess of PARP inhibitor (Fig. 5B and Supplementary Table 3 ). Research blood draws were obtained from 3 patients, each at 5 timepoints (1-3 minutes, 6-7 minutes, 26-39 minutes, 91-106 minutes and 163 minutes). Using a 2-phase decay curve, we determined the weighted blood half-life to be 1.98 minutes. At 30 minutes, and with decreasing blood pool concentration of the injected tracer, we detected a radiometabolite with a retention time of 13.5 -16.5 minutes (58 ± 7%) (Supplementary Fig 1A) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org /10.1101 /10. /2020 This study describes the cancer-related localization of [ 18 F]PARPi in mouse glioma models as well as in first-in-human-brain-cancer patients. Increased [ 18 F]PARPi uptake on PET was correlated with increased PARP1 expression of the brain cancer biospecimens. Ancillary [ 18 F]PARPi kinetic modeling, PARPi-FL biospecimen imaging and PARP inhibitor blockade confirmed that the uptake was cancer specific. Response Assessment in Neuro-Oncology (RANO) and RANO-brain metastasis (RANO-BM) rely on changes in enhancing size lesions to determine treatment efficacy or failure (14) (15) (16) . Despite the ubiquity of these and other similar standardized criteria in clinical trials, as well as their growing adoption in clinical practice, there is recognition of the need for advanced imaging techniques to complement these size measurements in treated cancers (17) . After radiation therapy, chemotherapy and/or immunotherapy, treatment related changes may occur with growing and/or new enhancing lesions that represent inflammatory-mediated changes rather than worsening cancers. Such treatment related changes include both early pseudoprogression occurring in less than 3 months or up to 6-12 months, as well as late radiation necrosis occurring many months or years later, which may occur in up to one-third or more of patients with primary and secondary brain cancers (18) (19) (20) (21) . We investigated a new radiotracer, [ 18 F]PARPi, to bridge this clinical problem. Pre-clinical research has demonstrated uptake in mouse glioma models that is strongly correlated with All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org /10.1101/2020.07.13.20141036 doi: medRxiv preprint PARP1 expression and high in cancers and low in normal tissues (5, 22, 23) . Furthermore, limited uptake was seen in experimentally induced radiation necrosis, despite the presence of blood-brain barrier disruption (5) . Consistent with previous understanding of the mechanism of PARP upregulation in response to DNA damage (11, 12, 24, 25) , we confirmed in humans that increased [ 18 F]PARPi uptake was correlated with active brain cancer and not with treatment related changes. This has significant implications for patient care, because the accurate and timely non-invasive diagnosis of those changes remain a remarkable imaging challenge. Patients with confirmed recurrent or progressive cancer should stop their current ineffective treatment and instead be considered for possible further resection, radiation therapy, chemotherapy and/or immunotherapy including clinical trials. In contrast, patients with confirmed treatment related changes should continue their current effective treatment and receive supportive care such as additional steroid therapy, and not embark on more aggressive invasive or investigational therapies. The correlation between [ 18 F]PARPi PET uptake and PARP1 expression confirms its importance in maintaining genome stability and apoptosis in glioblastoma (8), and suggests implications for informing treatment decisions. [ 18 F]PARPi PET also presents the potential for the noninvasive in vivo prediction of drug efficacy. Pre-therapy scans already play a role in certain cancers, such as I-123 pretherapy scans in differentiated thyroid cancers before I-131 radioablation (26) . Given specific localization uptake in brain cancers, [ 18 F]PARPi avidity may be useful to quantify PARP1 upregulation in cancer and subsequent sensitivity to systemic PARP inhibitor therapy. This is relevant for brain cancers as PARP inhibitors are being investigated in several ongoing clinical trials (NCT03150862). Besides this, PARP inhibitors are already approved by the U.S. Food and Drug All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 13 Administration (FDA) for treatment of solid cancers such as ovarian cancer (27) . PARP inhibitor proof of drug target engagement has been also demonstrated by PET in pre-clinical mouse xenograft models of small cell lung and ovarian cancers (28, 29) . Demonstrating avid [ 18 F]PARPi PET uptake may provide critical data to identify cancers receptive to subsequent PARP inhibitory therapy, versus cancers that may be resistant. Moreover, there are exciting efforts to develop targeted therapeutic options by adding radiotoxic isotopes directly to the olaparib inhibitor scaffold. A recently published study demonstrated promising results using a theragnostic Auger emitting PARP inhibitor (123I-MAPi) in a preclinical model. Taking advantage of the physical properties of Auger emission, dependent on the proximity of the electron emitter to the DNA to cause cellular damage, along with the biological expression of PARP1/2, much higher in cancer when compared to normal cells, it was possible to achieve lethal cancer doses with limited normal tissue toxicity (30) . Consistent with the role of PET as an imaging problem solver, the cancer specific avidity of [ 18 F]PARPi may also play a role in the differential diagnosis of newly diagnosed brain masses given the apparent lack of correlation with blood-brain barrier disruption that underpins many enhancing brain lesions. The avidity and thereby specificity of the [ 18 F]PARPi tracer in cancermimicking conditions such as tumefactive demyelinating disease, infarction and abscess, however, is still unknown warranting further research. One potential limitation of the study is the small human cohort size. Nevertheless, the results of this prospective, first-in-human-brain-cancer study suggest safety as well as a potential role for [ 18 F]PARPi PET imaging to discriminate between active brain cancer and treatment related All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 changes, which represents a significant clinical challenge for many patients. A second potential limitation is the absence of histopathology confirmation of cancer versus treatment related changes for 3 of the 7 lesions, in which the outcomes were determined by follow up per In conclusion, we present complementary preclinical data and first-in-human-brain-cancer data demonstrating that [ 18 F]PARPi uptake is specific to cancer and correlated with PARP1 expression. Although larger trials are necessary, we suggest a role for [ 18 F]PARPi in monitoring of patients with the common clinical dilemma of recurrent or progressive brain cancer versus treatment related changes, and future theragnostic applications for both systemic and combination radiotracer-treatment agents. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 Preclinical Radiochemistry [ 18 F]PARPi was synthesized using an optimized labeling procedure according to previously described methods (6, 31, 32) . The preclinical synthesis differs from the clinical synthesis in two ways: (1) (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo [8.8.8] Animal Work Brain cancer development was modeled in p53 deficient nestin/tv-a mice (ntva/p53 fl/fl mice) using a glioma model based on the RCAS/tv-a system (33, 34) . Animals were sacrificed 1 hour post injection, brains were extracted, frozen and sectioned. Coronal cryosections were exposed to a storage phosphor autoradiography plate (Fujifilm, BAS-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 MS2325, Fiji Photo Film) overnight at -20°C for radiotracer localization. Adjacent sections were co-stained with Hoechst 33342 and scanned for FITC/Dextran accumulation using a MIRAX scanner. Images were compared using ImageJ to analyze distribution of FITC-Dextran and (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. guidelines, was compliant with the Health Insurance Portability and Accountability Act regulations and approved by the local Institutional Review Board and Privacy Board. The authors all vouch for the accuracy and completeness of the data and analyses and for the adherence of the study to the protocol. All patients provided written informed consent before enrollment. The inclusion criteria for the study were patients harboring new or suspected recurrent brain cancer(s) with enhancing lesion(s) ≥ 1.5 cm in diameter. The patients were also required to be ≥ 18 years of age, able to undergo PET/MR scanning, and to receive intravenous gadolinium contrast. All women of childbearing age included in the study had a negative pregnancy test < 2 weeks prior to enrollment. The exclusion criteria were any contraindication to 3T MR scanning per departmental criteria, patient decision to withdraw from the study or failure to comply with protocol requirements. Cohort enrollment was halted at n=5 patients due to the COVID-19 pandemic induced interruption of all non-therapeutic clinical trials in early 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, 2020. . https://doi.org /10.1101 /10. /2020 Patient Imaging All scans were performed on a 3T PET/MR scanner (Signa, GE Medical Systems, Milwaukee, WI) with lutetium-based scintillator crystal arrays and silicon photomultiplier detectors integrated into the MR gantry to enable simultaneous PET and MR acquisition. PET images were acquired, after peripheral -usually the cephalic veinadministration of 10 mCi of [ 18 F]PARPi, with dynamic acquisition for 60 minutes, and additional static 10 minutes acquisitions at 60 minutes and 120 minutes. Volumes-of-interest (VOIs) for SUV measurements were manually placed by an experienced radiologist on lesions visualized by PET images and guided by co-registered MR images, then internally-contoured to select only lesion voxels above a visually guided threshold intensity to select all tracer-avid portions of the lesion for SUV measurements. These SUV measurements were obtained at 60 minutes (SUV60mean) and at 120 minutes (SUV120mean), as well as ratios normalized to the confluence of the cerebral venous sinuses (ratio SUV60mean and ratio SUV120mean). MR sequences were acquired using a 32-channel head coil without and with gadolinium contrast (gadobutrol 0.1 mmol/kg, max 10 mL, Bayer Healthcare, Whippany, NJ) according to the standardized brain cancer protocol (36, 37) . Per institutional standards, additional advanced imaging also included: 1) Dynamic contrast-enhanced (DCE) T1 perfusion with extended Tofts modeling analysis to calculate Ktrans and plasma volume maps to determine volume-of-interest ratio measurements for each enhancing lesion (NordicICE 2.3.14, NordicNeuroLab, Bergen, Norway); and 2) Delayed contrast images acquired 60-105 minutes after gadolinium injection with calculation of contrast clearance analysis maps (Elements, Brainlab AG, Munich, Germany) (38) and volume-ofinterest ratio measurements of voxels demonstrating contrast clearance (encoded in blue, representing cancer) divided by voxels demonstrating contrast clearance and contrast All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 accumulation (encoded in red, representing treatment related change) for each enhancing lesion (software provided by Yael Mardor, PhD, Sheba Medical Medical Center, Tel-Hashomer, Israel). Surgical resection was performed when clinically indicated as per the standard of care. One patient declined cancer resection and clinical and radiological outcomes were used as a surrogate for diagnosis. Resected specimens were classified as cancer when viable cancer tissue was present, and treatment related changes when no viable cancer tissue was present. If histology was not available, due to non-surgical treatment, then lesion outcomes were determined by clinical and imaging follow up based on the Response Assessment in Neuro-Oncology (RANO) criteria for primary brain cancers and the RANO brain metastasis (RANO-BM) criteria for secondary brain cancers (15, 16, 39) . In patients with brain metastases, maximum 5 enhancing lesions ≥ 1.5 cm in diameter were measured per patient. Per RANO and RANO-BM, respectively, progressive disease (PD) was defined as ≥ 25% increase in the product of perpendicular diameters or ≥ 20% increase in the sum of longest diameters or clinical worsening; partial response (PR) as ≥ 50% decrease in the product of perpendicular diameters or ≥ 30% decrease in the sum of longest diameters; complete response (CR) as the disappearance of all enhancing lesions; and stable disease (SD) as all other conditions. PR and CR required sustained effect for ≥1 month. Blood Time Activity Curves. Blood samples for tracer concentration and metabolite analysis were collected. Blood draws were obtained for 3 patients at 5 timepoints after tracer injection, activity counted, and metabolites analyzed (Fig. S1 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 Histopathological Assessment Lesion outcomes were determined by histopathology when available (n = 4). All cases were reviewed by an experienced neuropathologist. The presence of any viable cancer was considered cancer, and percentages were also recorded when possible. One tissue included both areas of cancer and areas of treatment related changes, which were quantified separately. PARP1 Immunohistochemistry Paraffin-embedded slides were processed at the molecular cytology core facility using previously described protocols (17) . Briefly, Anti-PARP1 rabbit monoclonal antibody (46D11, Cell Signaling Technology, Danvers, MA) (0.4 µg/mL) was incubated for 5 h, followed by 1 h of incubation with biotinylated goat anti-rabbit IgG (PK6106, Vector Labs, Burlingame, CA) at a 1:200 dilution. Slides were further scanned (Mirax, 3DHISTECH) to allow for digital histological correlation. Quantification of PARP1 was carried All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, . . https://doi.org/10.1101 doi: medRxiv preprint 21 out on digitalized slides. Thresholding was performed (Fiji, Image J) on brown, PARP1 marked with 3'-Diaminobenzidine (DAB) and blue (entire tissue) areas and the relative PARP1-positive area was calculated by dividing the brown (DAB) area by the blue (total tissue area). The entire image slide was encompassed for analysis. Paraffin-embedded slides were processed at the MSK molecular cytology core facility using previously described protocols (43). Slides were scanned (Mirax, 3DHISTECH, Budapest, Hungary) to allow for digital histological correlation. Freshly excised brain cancers obtained from the patients (n = 4) after surgery (whole-mount) were stained with a solution of 100 nM of PARPi-FL in 30% polyethylene glycol in phosphate buffered saline (PEG/PBS) for 5 minutes, as previously described (11) . For the blocking experiment, tissues were co-incubated with 100-fold of olaparib together with PARPi-FL. Nuclei were stained with a solution of 10 µg/mL of Hoechst 33342 in PBS. Images were acquired with a laser scanning confocal microscope (LSM880-Live, Zeiss, Germany) using 488 nm laser excitation for PARPi-FL (green), 405 nm for Hoechst (blue) and 561 nm (red) for autofluorescence. Quantification of intensity of PARPi-FL signal was calculated using Fiji (ImageJ) (12) by placing the region of interest on the Hoechst nuclear stain and calculating the signal emerged in that same area using the green channel. Nuclear accumulation of PARPi-FL was calculated using arbitrary units (A.U.). Statistical Analysis Statistical analysis of the tissue biospecimens were performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA) and R v3.6.0 (R Core Team (2018), R All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 22 Foundation for Statistical Computing, Vienna, Austria). Data points represent median values, and error bars represent standard deviations. Statistical analyses for the PARP1 expression on IHC were performed using Kruskal-Wallis test and the correlation with the SUVmax on 60 minutes using the Spearman correlation coefficient. Imaging data were examined using Wilcoxon rank sum tests. The blocking tissue experiment results were dichotomized at 3 due to the discrete nature of the data and analyzed with a chi-square test. Statistical significance was determined with p < 0.05. No correction for multiple testing was performed. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 24 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 25 Fig. 2 . Representation of the study schema Potential subjects were identified by a member of the patient's treatment team and referred to the investigator and staff of the study. Participation in the study was voluntary. Intervention consisted of one PET/MR examination with up to 3 scan times using [ 18 F]PARPi as a tracer (10 mCi) . Six blood draws (5 mL each) were taken: 5 to access the pharmacokinetics and distribution of the drug and one for complete blood count with differential and a complete metabolic panel to access toxicity. Vital signs included temperature, heart rate, blood pressure, oxygen saturation; none were out of normal range. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 ^One glioblastoma was treatment naïve *Melanoma patient had 3 brain lesions ≥ 1.5 cm All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 PARPi-FL uptake was seen in all cancers (lesions 2, 6 and 7). Faint signal was seen in treatment related changes (lesion #5). This differential PARP1 expression in cancer versus treatment related changes was also observed on immunohistochemistry between patients. (B) Differences in quantified PARP1 expression was seen in cancer (lesions #2, 6 and 7 -in blue) when compared to the tissue that only presented treatment related changes (lesion 5 -in pink). (B) Lesion #5, with no viable cancer, had median PARP1 expression over total tissue area of 3%, which was significantly lower than the expression in all cancer specimens, lesions #2, 6 and 7 -All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, . . https://doi.org/10.1101 doi: medRxiv preprint 29 7%, 10% and 14%, respectively, p < 0.001, Kruskal-Wallis test. (C) Correlation of PARP1 expression and the SUVmax of [ 18 F]PARPi at 60 minutes post injection. Scale bar in slides with high magnification correspond to 50 µm and overviews correspond to 0.5 cm. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, . . https://doi.org/10.1101 doi: medRxiv preprint 31 uptake seen on imaging (arrow points to high uptake) is believed to be due to difference in PARP1 expression seen at histology between areas of cancer and areas of treatment change. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 17, . . https://doi.org/10.1101 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 34 wrote the original draft. All authors reviewed and edited the drafts and approved the final manuscript. Funding: This work was supported by National Institutes of Health grants P30 CA008748, R01 CA204441, R43 CA228815 the Memorial Sloan Kettering Imaging and Radiation Sciences Program and the Memorial Sloan Kettering Molecularly Targeted Intraoperative Imaging Fund. The funding sources were not involved in study design, data collection and analysis, writing of the report, or the decision to submit this article for publication. Competing interests: RJY has financial interests and received funding from Agios, and consulted for Agios, Puma, ICON, and NordicNeuroLab, unrelated to this work. NSM has consulted for AztraZeneca. TR and SK are shareholders of Summit Biomedical Imaging and coinventors on filed U.S. patent (WO2016164771) that covers methods of use for PARPi-FL and Data and materials availability: All data associated with this study are present in the paper or the Supplementary Materials. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020 REFERENCES AND NOTES Acknowledgements: The authors are grateful for the contributions of Matthew Sellitti and the Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review Diagnostic Accuracy of Amino Acid and FDG-PET in Differentiating Brain Metastasis Recurrence from Radionecrosis after Radiotherapy: A Systematic Review and Meta-Analysis Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0 Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis Discriminating radiation injury from recurrent tumor with [(18)F]PARPi and amino acid PET in mouse models Fluorine-18 labeled poly (ADPribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[(18)F]fluoro-dglucose positron emission tomography in oral cancer imaging PET Imaging of PARP Expression Using (18)F-Olaparib PARP-1 protein expression in glioblastoma multiforme The role of PARP in DNA repair and its therapeutic exploitation Therapeutic applications of PARP inhibitors: anticancer therapy and beyond Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers Molecular Imaging of PARP Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Response Assessment in Neuro-Oncology Clinical Trials All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Response assessment criteria for brain metastases: proposal from the RANO group Clinical trial end points for high-grade glioma: the evolving landscape Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation Pseudoprogression: relevance with respect to treatment of high-grade gliomas Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma Radioiodinated PARP1 tracers for glioblastoma imaging PARP-1 Expression Quantified by [(18)F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? PARP Inhibitors in Ovarian Cancer Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts A PET imaging agent for evaluating PARP-1 expression in ovarian cancer Targeted brain tumor radiotherapy using an Auger emitter Target engagement imaging of PARP inhibitors in small-cell lung cancer Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted doi: medRxiv preprint Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma NIH Image to ImageJ: 25 years of image analysis Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM) Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering, Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Delayed contrast extravasation MRI: a new paradigm in neuro-oncology Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 17, . . https://doi.org/10.1101 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted July 17, 2020. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted . . https://doi.org/10.1101 /2020